Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBigLEN (mouse) is a GPR171 agonist. ProSAAS-derived neuropeptide. Regulates food intake in mice. Inhibits the release of glutamate onto parvocellular neurons of the paraventricular nucleus in a process dependent upon activation of postsynaptic G proteins.
M. Wt | 1756.03 |
Formula | C78H130N24O22 |
Sequence | LENPSPQAPARRLLPP |
Storage | Store at -20°C |
Purity | ≥95% (HPLC) |
CAS Number | 501036-69-7 |
PubChem ID | 131648250 |
InChI Key | UEWHHQZTIIRRRA-REWHPCPNSA-N |
Smiles | [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility | Soluble to 2 mg/ml in water |
References are publications that support the biological activity of the product.
Wardman et al (2011) ProSAAS-derived peptides are colocalized with neuropeptide Y and function as neuropeptides in the regulation of food intake. PLoS One 6 e28152 PMID: 22164236
Mack et al (2019) Neuropeptide PEN and its receptor GPR83: distribution, signaling, and regulation. ACS Chem.Neurosci. 10 1884 PMID: 30726666
If you know of a relevant reference for BigLEN (mouse), please let us know.
Keywords: BigLEN (mouse), BigLEN (mouse) supplier, GPR171, agonists, agonism, neuropeptide, proSAAS, food, intake, glutamate, release, parvocellular, neurons, 6304, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for BigLEN (mouse) include:
Richard D et al (2021) The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun 12 5857 PMID: 34615877
Do you know of a great paper that uses BigLEN (mouse) from Tocris? Please let us know.
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
I used this to screen for the activation of cell activity. I found the ideal concentrations to be around 1 - 25 uM to be ideal for my needs. It performed as expected and was easy to reconstitute. It stored at 2 mg/mL at -20C for more than 3months.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.